Profitability
Weight: 20%
F
0
- 5yr Avg ROIC -32.0%
- Operating Margin Trend -7.17 pp/yr
ENTA
Enanta Pharmaceuticals, Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 6.2 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
14
- 5yr Avg ROE -164.6%
- 5yr Share-Count CAGR 1.4%
Growth Quality
Weight: 15%
F
8
- 5yr Revenue CAGR -9.4%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 0/5
Cash Generation
Weight: 15%
F
0
- 5yr FCF Margin -101.5%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 20%
F
0
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) -9.88x
- Altman Z-Score -0.78
Stability
Weight: 15%
F
20
- EPS Volatility (σ/μ) 0.59
- Piotroski F-Score 3
- Negative-Revenue Years (5) 5/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.1 of 2 gurus held; 1 trimmed; 1 full exit.
- Holders
- 1 -1
- Avg Δ position
- -57.7%
- New buys
- 0
- Full exits
- 1